GlassScriptPhysician profile
Summer M Clay
NPI 1740680354
$7,685.62
in general payments reported to CMS, 2019-2025
41 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $1,118 · 2023: $2,053 · 2024: $2,040 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,857 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,856.95 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,593.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,059.49 | 2022-2025 | Caplyta |
| Abbvie INC. | $926.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $658.65 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $618.67 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $341.29 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $242.29 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $235.76 | 2025 | Fanapt |
| Lundbeck LLC | $218.94 | 2023-2025 | Rexulti |
| Pfizer INC. | $202.77 | 2021-2025 | |
| Amgen INC. | $190.31 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.80 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $117.23 | 2022-2023 | Eliquis |
| Dexcom, INC. | $103.75 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $95.98 | 2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.